Zoetis (ZTS) Tops Q4 EPS by 4c; Affirms FY16 EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Zoetis' (ZTS) Simparica Should Gain Approval in March - Piper Jaffray
February 17, 2016 8:19 AM ESTDespite reducing Zoetis Inc. (NYSE: ZTS) price target by 9%, Piper Jaffray analyst, Kevin Ellich kept his Outperform rating and sees a near term catalyst as Simparica prepares for launch and Apoquel finds a second API source.
ZTS reported solid Q4 results highlighted by 6% operational growth which included 30% operational growth in U.S. companion animal product sales. Revenue beat Street estimates even with... More
